Drug Patents owned by Merlion Pharms Gmbh

1. List of Xtoro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9119859 MERLION PHARMS GMBH Methods for treating otic infections
Jul, 2030

(7 years from now)

US9993483 MERLION PHARMS GMBH Compositions and methods for treating ophthalmic, octic, or nasal infections
Jul, 2030

(7 years from now)

US8536167 MERLION PHARMS GMBH Methods for treating ophthalmic, otic, or nasal infections
Aug, 2031

(8 years from now)

US9504691 MERLION PHARMS GMBH Finafloxacin suspension compositions
Nov, 2033

(10 years from now)

Do you want to check out XTORO patents from before 2022?

Drugs and Companies using FINAFLOXACIN ingredient

Market Authorisation Date: 17 December, 2014

Treatment: Treatment of acute otitis externa

Dosage: SUSPENSION/DROPS;OTIC

More Information on Dosage

XTORO family patents

9

United States

4

China

3

Japan

2

Canada

2

Mexico

2

Argentina

2

Brazil

2

Australia

2

South Africa

2

Russia

2

Spain

2

Korea, Republic of

2

Chile

2

European Union

1

Ukraine

1

Philippines

1

Uruguay

1

Taiwan

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic